CN102657838B - Application of traditional Chinese medicine composition in preparation of medicine for treating alcoholic hepatitis - Google Patents
Application of traditional Chinese medicine composition in preparation of medicine for treating alcoholic hepatitis Download PDFInfo
- Publication number
- CN102657838B CN102657838B CN 201210175705 CN201210175705A CN102657838B CN 102657838 B CN102657838 B CN 102657838B CN 201210175705 CN201210175705 CN 201210175705 CN 201210175705 A CN201210175705 A CN 201210175705A CN 102657838 B CN102657838 B CN 102657838B
- Authority
- CN
- China
- Prior art keywords
- fructus
- parts
- medicinal liquid
- crude drug
- thick paste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 206010019728 Hepatitis alcoholic Diseases 0.000 title claims abstract description 33
- 208000002353 alcoholic hepatitis Diseases 0.000 title claims abstract description 33
- 239000012567 medical material Substances 0.000 claims description 49
- 239000000796 flavoring agent Substances 0.000 claims description 35
- 235000019634 flavors Nutrition 0.000 claims description 35
- 239000000843 powder Substances 0.000 claims description 32
- 229940079593 drug Drugs 0.000 claims description 31
- 239000007788 liquid Substances 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000002775 capsule Substances 0.000 claims description 19
- 241001529849 Dracocephalum Species 0.000 claims description 18
- 241000218176 Corydalis Species 0.000 claims description 17
- 235000003935 Hippophae Nutrition 0.000 claims description 17
- 241000229143 Hippophae Species 0.000 claims description 17
- 241001495448 Impatiens <genus> Species 0.000 claims description 17
- 241000382297 Lagotis brachystachya Species 0.000 claims description 17
- 229930190166 impatien Natural products 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 15
- 239000009609 fructus phyllanthi Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000002481 ethanol extraction Methods 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 241000001522 Terminalia chebula Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 241001061906 Caragana Species 0.000 abstract 1
- 244000119298 Emblica officinalis Species 0.000 abstract 1
- 235000015489 Emblica officinalis Nutrition 0.000 abstract 1
- 240000000950 Hippophae rhamnoides Species 0.000 abstract 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 abstract 1
- 241000600550 Lagotis brevituba Species 0.000 abstract 1
- 244000086363 Pterocarpus indicus Species 0.000 abstract 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 240000000513 Santalum album Species 0.000 abstract 1
- 235000008632 Santalum album Nutrition 0.000 abstract 1
- 241000977603 Swertia chirayita Species 0.000 abstract 1
- 241001534869 Terminalia Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 9
- 108010082126 Alanine transaminase Proteins 0.000 description 9
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 9
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003862 glucocorticoid Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 3
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 3
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 description 2
- -1 hydroxypropyl Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229960001476 pentoxifylline Drugs 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010062070 Peritonitis bacterial Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an application of a traditional Chinese medicine composition in preparation of a medicine for treating alcoholic hepatitis. The traditional Chinese medicine composition is prepared by traditional Chinese medicines such as Tibetan caragana, phyllanthus emblica, lagotis brevituba, sandalwood padauk, swertia chirata, medicine terminalia fruit, seabuckthorn paste and rhubarb. Clinical experiments show that the traditional Chinese medicine composition has significant clinical curative effects on the alcoholic hepatitis.
Description
Technical field
The present invention relates to the application of a kind of Chinese medicine composition in preparation treatment alcoholic hepatitis medicine, belong to the Chinese herbal medicine application.
Background technology
Alcoholic hepatitis is the hepatic disease that causes due to long-term heavy drinking, can bring out even liver failure of popularity hepatic necrosis when seriously indulging in excessive drinking.This disease is one of common hepatic disease of China.The serious harm people's is healthy.Alcoholic hepatitis is also a Clinical typing of alcoholic liver disease, it is one group of clinical pathology syndrome that a large amount of necrosis of hepatocyte in a short time cause, can occur in or the basis without liver cirrhosis on, main manifestations is that Serum ALT, AST raise and serum total bilirubin obviously increases, and can raise with heating, peripheral blood neutrophil.The serious symptom alcoholic hepatitis refers to that the performance of liver failure appears in the alcoholic hepatitis patient, as disturbances of blood coagulation, jaundice, hepatic encephalopathy, acute renal failure, upper gastrointestinal hemorrhage etc., often with endotoxemia.
The topmost clinical manifestation of alcoholic hepatitis is jaundice to occur rapidly, and other sings and symptoms comprises that heating, ascites, near-end are of flaccid muscles etc., and hepatic encephalopathy can appear in serious symptom alcoholic hepatitis patient.Usually, alcoholic hepatitis patient's liver increases, liver is touched a tender spot the positive.Laboratory research shows, the sex expression of alcoholic hepatitis patient characteristic is: AST is normal〉2 times of Upper Limit of Normal Values, but seldom 300U/ml.And Serum ALT is lower, and AST/ALT is common〉2, but this feature is not had specificity and a susceptiveness.Peripheral blood leucocyte, neutrophil count, serum total bilirubin and INR (intemationalnormalized ratio.INR) raise simultaneously.Serum creatinine level raises, and the indication prognosis mala is because this is usually indicating the generation of hepatorenal syndrome and even dead closing on.
The medicine for the treatment of alcoholic hepatitis mainly contains glucocorticoid, pentoxifylline and other medicines etc. at present, wherein glucocorticoid suppresses the activity of transcription factor such as exciting albumen l (AP 1) and NF-KB by part, stop inflammatory process, can improve the serious symptom alcoholic hepatitis.But the glucocorticoid treatment alcoholic hepatitis remains dispute, and for Severe Acute alcoholic hepatitis patient, uses glucocorticoid to have higher mortality rate.And pentoxifylline is the inhibitor of phosphodiesterase, has multiple effect, comprise regulate TNF transcribe, reduce alcoholic hepatitis patient short-term case fatality rate.But multiple untoward reaction is arranged, wherein occur at first with symptom of digestive tract such as diarrhoea, vomiting, epigastrium pain, other untoward reaction symptoms comprise headache, skin erythema, spontaneous bacterial peritonitis, urinary tract infection etc.The other drug treatment is mainly directly to replenish the cell constituent of the film to comprise exogenous additional polyene phosphatidylcholine, promotion endogenous phosphatidylcholine (S one ademetionine) and glutathion generation etc.This class medicine or cell membrane courier's (as phosphoinositide) important component, and have antioxidation.The glycyrrhizic acid preparation can suppress the CS digestive enzyme, and endogenous CS is increased, and has antiinflammatory, antitoxin, antianaphylactic effect.The active component silymarin (guest) that extracts in Herba Silybi mariani has stronger antioxidation, the effect of fibrosis.But said medicine all can not fundamentally be cured alcoholic hepatitis.Therefore research and develop low toxicity, safe and effective alcoholic hepatitis medicine is significant.
Hide capsule for descend of blood fat and come from famous Tibetan medicine and pharmacology scholar Supreme Being agate pellet and increase " the doctor's work selected works " that Peng arranges, Tibetan language be called " Ju Rinia ", has so far the clinical practice history of more than 300 years, is Tibetan medicine's be used to purify the blood representative prescription of grease removal.Hide capsule for descend of blood fat and be recorded in the national drug standards, standard number: WS-10864 (ZD-0864)-2002.Formed by ZANGJINJIER, Fructus Phyllanthi, Lagotis brachystachya Maxim, Lignum pterocarpi indici, Indian Herba Swertiae bimaculatae, Fructus Chebulae, Fructus Hippophae extractum, Radix Et Rhizoma Rhei, Corydalis impatiens (Pall.) Fisch., tangut dragonhead, Rhizoma Zingiberis.Function cures mainly and is Tibetan medicine: passage blood vessels, circulation of qi promoting removing heat from blood.Be used for the caused hyperlipemia of heat in blood.The traditional Chinese medical science: phlegm reduction of blood circulation promoting.Be used for the hyperlipemia that the resistance of expectorant blood stasis causes.
Patent CN201110188604.X discloses a kind of method of quality control of hiding blood-fat-reducing preparation, comprises the discrimination method of tangut dragonhead, the content assaying method of aloe-emodin, chrysophanic acid, emodin, chrysophanol, 5 kinds of main components of physcione in Radix Et Rhizoma Rhei.The application of unexposed this pharmaceutical composition of this patent in preparation treatment alcoholic hepatitis medicine.
Patent CN100389816C discloses a kind of Tibetan medicinal preparation for the treatment of hyperlipemia and preparation method thereof, comprises the superfine powder of crude drug first being made 0.1-50 μ m, and then makes capsule and tablet.The application of unexposed this pharmaceutical composition of this patent in preparation treatment alcoholic hepatitis medicine.
Through in National IP Network, incomparably data base and tie up general database scientific and technological literature database retrieval, visible document 1: Fructus Mume, Liu Youju, Chen Qiuhong. Tibetan medicine is hidden capsule for descend of blood fat toxicologic study [J]. Asia-Pacific traditional medicine, 2012,2.Document 2: Zhu Yanmei, Dorje, Chen Qiuhong. gold is scolded capsule for descend of blood fat to hyperlipidemia rats blood fat and hemorheological impact [J]. Qinghai Medicine College's journal, 2004,25 (2).Document 3: Chen Qiuhong, Zhou Xiaomei, Yang Quanyu. gold is scolded blood fat and the hemorheology improvement effect research [J] of capsule for descend of blood fat. Chinese Journal of Modern Applied Pharmacy magazine, 2004,21 (4).Document 4: Zhou Xiaomei, Chen Qiuhong, Yang Quanyu. gold is scolded the Regulating Blood Lipid Effect research [J] of capsule for descend of blood fat. Chinese patent medicine, 2003,25 (11).Document 5: Zhou Xiaomei, Dorje, Fan Xiuru. gold is scolded capsule for descend of blood fat to the hemorheological impact of hyperlipidemia rats [J]. Shandong journal of Chinese medicine, 2003,22 (8).The all application of unexposed this pharmaceutical composition in preparation treatment alcoholic hepatitis medicine of above-mentioned document 1-5.
Summary of the invention
The purpose of this invention is to provide the application of a kind of Chinese medicine composition in preparation treatment alcoholic hepatitis medicine.
The application of a kind of Chinese medicine composition in preparation treatment alcoholic hepatitis medicine, this Chinese medicine composition is made by the crude drug of following weight portion:
ZANGJINJIER 20-60 part, Fructus Phyllanthi 15-45 part, Lagotis brachystachya Maxim 10-30 part, Lignum pterocarpi indici 10-30 part, Indian Herba Swertiae bimaculatae 10-30 part, Fructus Chebulae 10-30 part, Fructus Hippophae extractum 10-30 part, Radix Et Rhizoma Rhei 10-30 part, Corydalis impatiens (Pall.) Fisch. 10-30 part, tangut dragonhead 10-30 part, Rhizoma Zingiberis 8-24 part.
The weight ratio of Chinese medicine composition Raw medicine of the present invention is preferably:
39.3 parts of ZANGJINJIER, 31.4 parts of Fructus Phyllanthis, 23.5 parts of Lagotis brachystachya Maxims, 23.5 parts of Lignum pterocarpi indici, 23.5 parts of Indian Herba Swertiae bimaculataes, 23.5 parts of Fructus Chebulaes, 23.5 parts of Fructus Hippophae extractums, 23.5 parts of Radix Et Rhizoma Rhei, 23.5 parts of Corydalis impatiens (Pall.) Fisch.s, 23.5 parts of tangut dragonheads, 15.8 parts of Rhizoma Zingiberiss.
In application of the present invention, this Chinese medicine composition active component is made by following steps:
A) get ZANGJINJIER, Lagotis brachystachya Maxim, tangut dragonhead, Fructus Phyllanthi, Fructus Chebulae, Radix Et Rhizoma Rhei totally 6 flavor medical materials by the crude drug composition and ratio, extracting in water 1-4 time, the amount that at every turn adds water is 6-14 times of 6 flavor medical material gross weights, extracting temperature is 50-100 ℃, the each extraction 1-4 hour, filter, merge medicinal liquid, the thick paste A of relative density 1.20-1.40 when medicinal liquid is evaporated to 50 ℃;
B) get Indian Herba Swertiae bimaculatae, Corydalis impatiens (Pall.) Fisch. totally 2 flavor medical materials by the crude drug composition and ratio, add percent by volume 50-95% ethanol extraction 1-4 time, the amount that at every turn adds 50-95% ethanol is 8-12 times of 2 flavor medical material gross weights, extracting temperature is 50-80 ℃, the each extraction 1-3 hour filters, and merges medicinal liquid, the medicinal liquid concentrating under reduced pressure, the thick paste B of relative density 1.20-1.40 when being concentrated into 50 ℃;
C) get Fructus Hippophae extractum, Lignum pterocarpi indici, Rhizoma Zingiberis totally 3 flavor medical materials by the crude drug composition and ratio, be ground into fine powder, get medical material fine powder C.
D) the thick paste B that the thick paste A that step a) is obtained and step b) obtain merges, and oven dry is ground into fine powder, the medical material fine powder C that adds step c) to obtain, and mixing namely gets Chinese medicine composition of the present invention.
in application of the present invention, described Chinese medicine composition can be prepared into capsule, tablet, granule, a kind of in powder or oral liquid can realize for making above-mentioned dosage form, and needing in these dosage forms of preparation be to add pharmaceutically acceptable adjuvant, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic etc., filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc., disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc., lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc., binding agent comprises starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc., sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc., correctives comprises: sweeting agent and various essence, antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and salt thereof, benzalkonium bromide, the acetic acid chloroethene is fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods.
Above-described medicine capsule, its preparation method are to be made by following steps:
A) get ZANGJINJIER, Lagotis brachystachya Maxim, tangut dragonhead, Fructus Phyllanthi, Fructus Chebulae, Radix Et Rhizoma Rhei totally 6 flavor medical materials by the crude drug composition and ratio, extracting in water 2 times, the amount that at every turn adds water is 10 times of 6 flavor medical material gross weights, reflux, extract,, the each extraction 2 hours, filter, merge medicinal liquid, the thick paste A of relative density 1.30 when medicinal liquid is evaporated to 50 ℃;
B) get Indian Herba Swertiae bimaculatae, Corydalis impatiens (Pall.) Fisch. totally 2 flavor medical materials by the crude drug composition and ratio, add percent by volume 70% ethanol extraction 2 times, the amount that at every turn adds 70% ethanol is 10 times of 2 flavor medical material gross weights, reflux, extract,, the each extraction 2 hours filters, and merges medicinal liquid, the medicinal liquid concentrating under reduced pressure, the thick paste B of relative density 1.25 when being concentrated into 50 ℃;
C) get Fructus Hippophae extractum, Lignum pterocarpi indici, Rhizoma Zingiberis totally 3 flavor medical materials by the crude drug composition and ratio, be ground into fine powder, get medical material fine powder C.
D) the thick paste B that the thick paste A that step a) is obtained and step b) obtain merges, and oven dry is ground into fine powder, the medical material fine powder C that adds step c) to obtain, and mixing incapsulates, and get final product.
The pass of weight portion of the present invention and parts by volume is g/ml or kg/L.
The present invention has following advantage:
1. the present invention takes into full account the character of ingredient, clinical disease needs, and physiological conditions of medication object, pathologic condition etc., adopt new extraction preparation method, be prepared from, compare with the preparation of traditional method preparation, having overcome prior art with the pharmaceutical composition of method of the present invention preparation is crude drug and pulverizes and be used as medicine, be not suitable for the shortcoming of modern formulation, adopt the pharmaceutical composition of the technology of the present invention gained to can be used for preparing the various modern dosage forms such as capsule, granule, tablet, powder and various oral liquids.
2. the invention provides the application of a kind of Chinese medicine composition in the medicine of preparation treatment alcoholic hepatitis, prove by clinical trial, this pharmaceutical composition is applied to the alcoholic hepatitis patient, and total effective rate 87.3% can be used for the treatment of alcoholic hepatitis.
Essence for a better understanding of the present invention in " treatment alcoholic hepatitis " result of the test, illustrates that it is in the new application of pharmaceutical field below by this pharmaceutical composition of clinical observation.
Test example 1: the clinical observation for the treatment of alcoholic hepatitis
Case enters the group standard
The diagnostic criteria of the alcoholic liver disease that China's medical association's hepatopathy branch fatty liver and alcoholic liver disease group are formulated enters group according in October, 2010:
1) long-term history of drinking history, generally surpass 5 years, amounts to ethanol amount 〉=40g/d, women 〉=20g/d, or interior heavy drinking history (〉 80g/d of 2 weeks);
2) aspartate aminotransferase (AST) rising amplitude is obviously greater than alanine aminotransferase (ALT) rising amplitude, and AST/ALT 〉=2;
3) hepatitis that except, other causes of disease cause;
4) treatment front 1 monthly not with excessively obviously falling the enzyme medicine.
The test grouping
MethodsThe cases enrolled successively is divided into two groups at random according to being admitted to hospital: test group 63 examples, and matched group 63 examples, GP TH all obtains the patient and family members agree, liver zymetology indicator difference not statistically significant before the sex of two groups, age, the course of disease, iconography and treatment.
The scheme of taking medicine
Advise patient's teetotalism during treatment, suitably reduce energy intake.Test group patient gives embodiment 1 preparation, and is oral, one time 5,2 times on the one, 4 weeks of the course for the treatment of.The matched group patient gives former preparation and hides capsule for descend of blood fat, scolds the production and marketing of Tibetan medicine limited company by the Qinghai gold, and is oral, one time 5,2 times on the one, 4 weeks of the course for the treatment of.
Observation index
The curative effect evaluation index
1) sings and symptoms: comprise weak, anorexia, uncomfortable liver area, hepatosplenomegaly etc.
2) liver function: aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), total bilirubin (TBiL).
Safety indexes
Hematuria is conventional, renal function
Curative effect judging standard
Produce effects: cardinal symptom and sign disappear, and liver function recovery is normal;
Effectively: cardinal symptom and sign are obviously improved, and ALT, AST, GGT, TBiL descend 75%;
Invalid: as not reach above-mentioned standard.
Obvious effective rate and effective percentage add up to total effective rate.
Statistical procedures:
Use SPSS l7.0 statistical software and carry out statistical analysis, two sample rates relatively use χ
2Check, the index determining result is relatively checked with t.
Result of the test
Before and after table 1 treatment, the liver function situation relatively
Annotate:
*, with the treatment before compare, P＜0.01
Table 1 result shows: before and after treatment, two groups of patient's liver function indexs have obtained obvious improvement, point out this medical instrument that hepatoprotective effect is arranged.
Table 2 liang group Clinical efficacy comparison [n (%)]
χ
2Check is compared with matched group,
*P＜0.05
Table 2 result shows: the routine patient of former preparation 63, and produce effects 39 examples, effective 9 examples, invalid 15 examples, total effective rate is 76.2%; The embodiment 1 routine patient of preparation group 63, produce effects 43 examples, effective 12 examples, invalid 8 examples, total effective rate is 87.3%.Compare with former preparation group, embodiment 1 preparation group total effective rate obviously improves.Point out former preparation Tibetan capsule for descend of blood fat and embodiment 1 preparation all to can be used for treating alcoholic hepatitis, and embodiment 1 preparation for treating alcoholic hepatitis clinical efficacy significantly is better than former preparation.
In addition, before and after the patient takes medicine, renal function, hematuria routine all within normal range, and have no obvious untoward reaction, point out this medicine clinical practice safe.
The specific embodiment
Following embodiment is used for illustrating the preparation of Chinese medicine composition of the present invention, but it can not consist of any restriction to scope of the present invention.
Embodiment 1 Chinese medicinal composition capsules agent
Formula:
ZANGJINJIER 39.3g, Fructus Phyllanthi 31.4g, Lagotis brachystachya Maxim 23.5g, Lignum pterocarpi indici 23.5g, Indian Herba Swertiae bimaculatae 23.5g, Fructus Chebulae 23.5g, Fructus Hippophae extractum 23.5g, Radix Et Rhizoma Rhei 23.5g, Corydalis impatiens (Pall.) Fisch. 23.5g, tangut dragonhead 23.5g, Rhizoma Zingiberis 15.8g.
Preparation method:
A) get ZANGJINJIER, Lagotis brachystachya Maxim, tangut dragonhead, Fructus Phyllanthi, Fructus Chebulae, Radix Et Rhizoma Rhei totally 6 flavor medical materials by the crude drug composition and ratio, extracting in water 2 times, the amount that at every turn adds water is 10 times of 6 flavor medical material gross weights, reflux, extract,, the each extraction 2 hours, filter, merge medicinal liquid, the thick paste A of relative density 1.30 when medicinal liquid is evaporated to 50 ℃;
B) get Indian Herba Swertiae bimaculatae, Corydalis impatiens (Pall.) Fisch. totally 2 flavor medical materials by the crude drug composition and ratio, add percent by volume 70% ethanol extraction 1-4 time, the amount that at every turn adds 70% ethanol is 10 times of 2 flavor medical material gross weights, reflux, extract,, the each extraction 2 hours filters, and merges medicinal liquid, the medicinal liquid concentrating under reduced pressure, the thick paste B of relative density 1.25 when being concentrated into 50 ℃;
C) get Fructus Hippophae extractum, Lignum pterocarpi indici, Rhizoma Zingiberis totally 3 flavor medical materials by the crude drug composition and ratio, be ground into 80 order fine powders, get medical material fine powder C;
D) the thick paste B that the thick paste A that step a) is obtained and step b) obtain merges, and oven dry is ground into fine powder, the medical material fine powder C that adds step c) to obtain, mixing, 1000 capsules of packing into.
Usage and dosage: oral, one time 5,2 times on the one.
Embodiment 2 Chinese medicine composition tablets
Formula:
ZANGJINJIER 39.3g, Fructus Phyllanthi 31.4g, Lagotis brachystachya Maxim 23.5g, Lignum pterocarpi indici 23.5g, Indian Herba Swertiae bimaculatae 23.5g, Fructus Chebulae 23.5g, Fructus Hippophae extractum 23.5g, Radix Et Rhizoma Rhei 23.5g, Corydalis impatiens (Pall.) Fisch. 23.5g, tangut dragonhead 23.5g, Rhizoma Zingiberis 15.8g.
Preparation method:
A) get ZANGJINJIER, Lagotis brachystachya Maxim, tangut dragonhead, Fructus Phyllanthi, Fructus Chebulae, Radix Et Rhizoma Rhei totally 6 flavor medical materials by the crude drug composition and ratio, extracting in water 1 time, the amount that at every turn adds water is 14 times of 6 flavor medical material gross weights, extracting temperature is 50 ℃, the each extraction 4 hours, filter, merge medicinal liquid, the thick paste A of relative density 1.20 when medicinal liquid is evaporated to 50 ℃;
B) get Indian Herba Swertiae bimaculatae, Corydalis impatiens (Pall.) Fisch. totally 2 flavor medical materials by the crude drug composition and ratio, add percent by volume 50% ethanol extraction 1 time, the amount that at every turn adds 50% ethanol is 12 times of 2 flavor medical material gross weights, extracting temperature is 80 ℃, the each extraction 3 hours filters, and merges medicinal liquid, the medicinal liquid concentrating under reduced pressure, the thick paste B of relative density 1.20 when being concentrated into 50 ℃;
C) get Fructus Hippophae extractum, Lignum pterocarpi indici, Rhizoma Zingiberis totally 3 flavor medical materials by the crude drug composition and ratio, be ground into fine powder, get medical material fine powder C.
D) the thick paste B that the thick paste A that step a) is obtained and step b) obtain merges, and oven dry is ground into fine powder, the medical material fine powder C that adds step c) to obtain, and mixing is made 1000 according to the conventional formulation method.
Embodiment 3 Chinese medicinal composition granules
Formula:
ZANGJINJIER 39.3g, Fructus Phyllanthi 31.4g, Lagotis brachystachya Maxim 23.5g, Lignum pterocarpi indici 23.5g, Indian Herba Swertiae bimaculatae 23.5g, Fructus Chebulae 23.5g, Fructus Hippophae extractum 23.5g, Radix Et Rhizoma Rhei 23.5g, Corydalis impatiens (Pall.) Fisch. 23.5g, tangut dragonhead 23.5g, Rhizoma Zingiberis 15.8g.
Preparation method:
A) get ZANGJINJIER, Lagotis brachystachya Maxim, tangut dragonhead, Fructus Phyllanthi, Fructus Chebulae, Radix Et Rhizoma Rhei totally 6 flavor medical materials by the crude drug composition and ratio, extracting in water 4 times, the amount that at every turn adds water is 6 times of 6 flavor medical material gross weights, extracting temperature is 95 ℃, the each extraction 1 hour, filter, merge medicinal liquid, the thick paste A of relative density 1.40 when medicinal liquid is evaporated to 50 ℃;
B) get Indian Herba Swertiae bimaculatae, Corydalis impatiens (Pall.) Fisch. totally 2 flavor medical materials by the crude drug composition and ratio, add percent by volume 95% ethanol extraction 4 times, the amount that at every turn adds 95% ethanol is 8 times of 2 flavor medical material gross weights, extracting temperature is 80 ℃, the each extraction 1 hour filters, and merges medicinal liquid, the medicinal liquid concentrating under reduced pressure, the thick paste B of relative density 1.40 when being concentrated into 50 ℃;
C) get Fructus Hippophae extractum, Lignum pterocarpi indici, Rhizoma Zingiberis totally 3 flavor medical materials by the crude drug composition and ratio, be ground into fine powder, get medical material fine powder C.
D) thick paste B that the thick paste A that step a) is obtained and step b) obtain merges, and oven dry is ground into fine powder, the medical material fine powder C that adds step c) to obtain, and mixing makes the 1000g granule according to the conventional formulation method, packing and get final product.
Embodiment 4 Chinese medicinal composition capsules agent
Formula:
ZANGJINJIER 20g, Fructus Phyllanthi 45g, Lagotis brachystachya Maxim 10g, Lignum pterocarpi indici 30g, Indian Herba Swertiae bimaculatae 10g, Fructus Chebulae 30g, Fructus Hippophae extractum 10g, Radix Et Rhizoma Rhei 30g, Corydalis impatiens (Pall.) Fisch. 10g, tangut dragonhead 30g, Rhizoma Zingiberis 8g.
Preparation method and usage and dosage are with embodiment 1.
Embodiment 5 Chinese medicinal composition capsules agent
Formula:
ZANGJINJIER 60g, Fructus Phyllanthi 15g, Lagotis brachystachya Maxim 30g, Lignum pterocarpi indici 10g, Indian Herba Swertiae bimaculatae 30g, Fructus Chebulae 10g, Fructus Hippophae extractum 30g, Radix Et Rhizoma Rhei 10g, Corydalis impatiens (Pall.) Fisch. 30g, tangut dragonhead 10g, Rhizoma Zingiberis 24g.
Preparation method and usage and dosage are with embodiment 1.
Claims (3)
1. the application of Chinese medicine composition in preparation treatment alcoholic hepatitis medicine, is characterized in that, this Chinese medicine composition is made by the crude drug of following weight portion:
ZANGJINJIER 20-60 part, Fructus Phyllanthi 15-45 part, Lagotis brachystachya Maxim 10-30 part, Lignum pterocarpi indici 10-30 part, Indian Herba Swertiae bimaculatae 10-30 part, Fructus Chebulae 10-30 part, Fructus Hippophae extractum 10-30 part, Radix Et Rhizoma Rhei 10-30 part, Corydalis impatiens (Pall.) Fisch. 10-30 part, tangut dragonhead 10-30 part, Rhizoma Zingiberis 8-24 part;
The dosage form of described Chinese medicine composition is capsule, tablet, granule, powder or oral liquid;
The active component of this Chinese medicine composition is to be made by following steps:
A) get ZANGJINJIER, Lagotis brachystachya Maxim, tangut dragonhead, Fructus Phyllanthi, Fructus Chebulae, Radix Et Rhizoma Rhei totally 6 flavor medical materials by the crude drug composition and ratio, extracting in water 1-4 time, the amount that at every turn adds water is 6-14 times of 6 flavor medical material gross weights, extracting temperature is 50-100 ℃, the each extraction 1-4 hour, filter, merge medicinal liquid, the thick paste A of relative density 1.20-1.40 when medicinal liquid is evaporated to 50 ℃;
B) get Indian Herba Swertiae bimaculatae, Corydalis impatiens (Pall.) Fisch. totally 2 flavor medical materials by the crude drug composition and ratio, add percent by volume 50-95% ethanol extraction 1-4 time, the amount that at every turn adds 50-95% ethanol is 8-12 times of 2 flavor medical material gross weights, extracting temperature is 50-80 ℃, the each extraction 1-3 hour filters, and merges medicinal liquid, the medicinal liquid concentrating under reduced pressure, the thick paste B of relative density 1.20-1.40 when being concentrated into 50 ℃;
C) get Fructus Hippophae extractum, Lignum pterocarpi indici, Rhizoma Zingiberis totally 3 flavor medical materials by the crude drug composition and ratio, be ground into fine powder, get medical material fine powder C;
D) the thick paste B that the thick paste A that step a) is obtained and step b) obtain merges, and oven dry is ground into fine powder, the medical material fine powder C that adds step c) to obtain, and mixing namely gets Chinese medicine composition.
2. application as claimed in claim 1, is characterized in that, this Chinese medicine composition is made by the crude drug of following weight portion:
39.3 parts of ZANGJINJIER, 31.4 parts of Fructus Phyllanthis, 23.5 parts of Lagotis brachystachya Maxims, 23.5 parts of Lignum pterocarpi indici, 23.5 parts of Indian Herba Swertiae bimaculataes, 23.5 parts of Fructus Chebulaes, 23.5 parts of Fructus Hippophae extractums, 23.5 parts of Radix Et Rhizoma Rhei, 23.5 parts of Corydalis impatiens (Pall.) Fisch.s, 23.5 parts of tangut dragonheads, 15.8 parts of Rhizoma Zingiberiss.
3. application as claimed in claim 1, is characterized in that, described medicine capsule is to be made by following steps:
A) get ZANGJINJIER, Lagotis brachystachya Maxim, tangut dragonhead, Fructus Phyllanthi, Fructus Chebulae, Radix Et Rhizoma Rhei totally 6 flavor medical materials by the crude drug composition and ratio, extracting in water 2 times, the amount that at every turn adds water is 10 times of 6 flavor medical material gross weights, reflux, extract,, the each extraction 2 hours, filter, merge medicinal liquid, the thick paste A of relative density 1.30 when medicinal liquid is evaporated to 50 ℃;
B) get Indian Herba Swertiae bimaculatae, Corydalis impatiens (Pall.) Fisch. totally 2 flavor medical materials by the crude drug composition and ratio, add percent by volume 70% ethanol extraction 1-4 time, the amount that at every turn adds 70% ethanol is 10 times of 2 flavor medical material gross weights, reflux, extract,, the each extraction 2 hours filters, and merges medicinal liquid, the medicinal liquid concentrating under reduced pressure, the thick paste B of relative density 1.25 when being concentrated into 50 ℃;
C) get Fructus Hippophae extractum, Lignum pterocarpi indici, Rhizoma Zingiberis totally 3 flavor medical materials by the crude drug composition and ratio, be ground into 80 order fine powders, get medical material fine powder C;
D) the thick paste B that the thick paste A that step a) is obtained and step b) obtain merges, and oven dry is ground into fine powder, the medical material fine powder C that adds step c) to obtain, and mixing incapsulates and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210175705 CN102657838B (en) | 2012-05-31 | 2012-05-31 | Application of traditional Chinese medicine composition in preparation of medicine for treating alcoholic hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210175705 CN102657838B (en) | 2012-05-31 | 2012-05-31 | Application of traditional Chinese medicine composition in preparation of medicine for treating alcoholic hepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102657838A CN102657838A (en) | 2012-09-12 |
| CN102657838B true CN102657838B (en) | 2013-11-06 |
Family
ID=46767505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210175705 Active CN102657838B (en) | 2012-05-31 | 2012-05-31 | Application of traditional Chinese medicine composition in preparation of medicine for treating alcoholic hepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102657838B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040909B (en) * | 2013-01-25 | 2014-04-23 | 西藏福田藏医药研究开发有限公司 | Tibetan medicine composition and application of composition in preparation of products for preventing and treating alcoholic liver diseases |
| CN107007809A (en) * | 2017-05-25 | 2017-08-04 | 山东省疾病预防控制中心 | It is a kind of for pharmaceutical composition of alcoholic hepatitis and its preparation method and application |
| CN108813608A (en) * | 2018-05-25 | 2018-11-16 | 陕西黄龙国寿堂生物工程有限公司 | A kind of production method of sea-buckthorn wilsonii cream |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660323A (en) * | 2004-12-19 | 2005-08-31 | 青海君吒药业有限公司 | 'Qiwei gandanqing' capsule for treating disease of liver and gall |
| CN1709447A (en) * | 2005-07-06 | 2005-12-21 | 甘肃奇正藏药有限公司 | Tibetan medicine formulation for treating hyperlipemia, and its preparing method |
| CN1857615A (en) * | 2006-03-23 | 2006-11-08 | 张玲 | Medicine for treating hepatitis and cholecystitis and its preparing method and application |
| CN101422523A (en) * | 2008-12-02 | 2009-05-06 | 昆明振华制药厂有限公司 | Health-care preparation capable of alleviating a hangover and protecting the liver and preparation method thereof |
| CN102058817A (en) * | 2010-11-01 | 2011-05-18 | 西藏金哈达药业有限公司 | Tibetan medicinal preparation for treating liver diseases |
| US20120015061A1 (en) * | 2010-01-19 | 2012-01-19 | Mukesh Harilal Shukla | Plant extracts composition for the treatment of liver dysfunction-jaundice |
| CN102397517A (en) * | 2011-07-05 | 2012-04-04 | 山东阿如拉药物研究开发有限公司 | Quality control method of traditional Tibetan medicinal lipid lowering preparation |
-
2012
- 2012-05-31 CN CN 201210175705 patent/CN102657838B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660323A (en) * | 2004-12-19 | 2005-08-31 | 青海君吒药业有限公司 | 'Qiwei gandanqing' capsule for treating disease of liver and gall |
| CN1709447A (en) * | 2005-07-06 | 2005-12-21 | 甘肃奇正藏药有限公司 | Tibetan medicine formulation for treating hyperlipemia, and its preparing method |
| CN1857615A (en) * | 2006-03-23 | 2006-11-08 | 张玲 | Medicine for treating hepatitis and cholecystitis and its preparing method and application |
| CN101422523A (en) * | 2008-12-02 | 2009-05-06 | 昆明振华制药厂有限公司 | Health-care preparation capable of alleviating a hangover and protecting the liver and preparation method thereof |
| US20120015061A1 (en) * | 2010-01-19 | 2012-01-19 | Mukesh Harilal Shukla | Plant extracts composition for the treatment of liver dysfunction-jaundice |
| CN102058817A (en) * | 2010-11-01 | 2011-05-18 | 西藏金哈达药业有限公司 | Tibetan medicinal preparation for treating liver diseases |
| CN102397517A (en) * | 2011-07-05 | 2012-04-04 | 山东阿如拉药物研究开发有限公司 | Quality control method of traditional Tibetan medicinal lipid lowering preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102657838A (en) | 2012-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103316219A (en) | Traditional Chinese medicinal preparation for treating phthisis and preparation method thereof | |
| CN102657838B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating alcoholic hepatitis | |
| CN104825788A (en) | Application of traditional Chinese medicine composition in preparation of drug for treating transient ischemic attack | |
| WO2013155995A1 (en) | Red yeast and kudzu root pharmaceutical composition for regulating blood lipids and preparation method therefor | |
| CN101829291B (en) | Traditional Chinese medicine preparation for treating rheumatism and preparation method thereof | |
| CN111588757A (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in stable phase and preparation method thereof | |
| CN107468955B (en) | Traditional Chinese medicine for treating gouty arthritis and preparation method | |
| CN105233150A (en) | Traditional Chinese medicine composition and application thereof | |
| CN103751450A (en) | Composition for treating diabetic nephropathy | |
| CN103768129B (en) | Drug composition for preventing or treating hypertension | |
| CN105749127A (en) | Pharmaceutic preparation for treating stomach cancer and application thereof | |
| CN101837104B (en) | Hyperlipidemia treating capsules | |
| CN113181250B (en) | Medicine for treating coronary heart disease and preparation method thereof | |
| CN104547026A (en) | Preparation method and application of salvia miltiorrhiza leave and panax pseudo-ginseng extract | |
| CN104013676B (en) | Buddleja officinalis and application of extract thereof in drug preparation | |
| CN106138494B (en) | Kidney nourishing composition and production method thereof | |
| CN102940656B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN102940674B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| WO2013155997A1 (en) | Blood lipid-regulating red yeast ligusticum chuanxiong pharmaceutical composition and preparation method therefor | |
| CN111068010B (en) | Traditional Chinese medicine composition for treating refractory idiopathic membranous nephropathy and application thereof | |
| CN101926848B (en) | Medicinal composition for treating heart cerebrovascular diseases and preparation thereof | |
| CN107233430B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN104547247A (en) | Applications of pharmaceutical composition in preparation of drug for treating viral cold | |
| CN106309902B (en) | Traditional Chinese medicine granule for treating diffuse interstitial pulmonary fibrosis yin deficiency and internal heat syndrome | |
| CN105535923A (en) | Leech small peptide effective part composition for treating kidney diseases and cardiovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SHANDONG JINHE DRUG RESEARCH AND DEVELOPMENT CO., Free format text: FORMER NAME: SHANDONG ARURA PHARMACEUTICAL RESEARCH + DEVELOPMENT CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: The 250101 Ji'nan Road, Shandong province hi tech Development Zone, No. 322 room 501-506 Patentee after: SHANDONG JINHE DRUG RESEARCH DEVELOPMENT CO.,LTD. Address before: The 250101 Ji'nan Road, Shandong province hi tech Development Zone, No. 322 room 501-506 Patentee before: SHANDONG ARURA PHARMACEUTICAL RESEARCH & DEVELOPMENT Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20161221 Address after: Two Baoan District road Xin'an Longjing street Shenzhen city Guangdong province 518000 3, COFCO Property Group Center on the first floor Patentee after: Shenzhen students medicine electricity supplier Co.,Ltd. Address before: The 250101 Ji'nan Road, Shandong province hi tech Development Zone, No. 322 room 501-506 Patentee before: SHANDONG JINHE DRUG RESEARCH DEVELOPMENT CO.,LTD. |
|
| TR01 | Transfer of patent right | ||
| CP03 | Change of name, title or address |
Address after: First floor of Zhongliang Real Estate Group Center, No. 3 Longjing Second Road, Xin'an Street, Baoan District, Shenzhen City, Guangdong Province Patentee after: Shenzhen Shenxiang Society Technology Co.,Ltd. Address before: 518000 First Floor of Zhongliang Real Estate Group Center, No. 3 Longjing Second Road, Xin'an Street, Baoan District, Shenzhen City, Guangdong Province Patentee before: Shenzhen students medicine electricity supplier Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190530 Address after: 8001, 8th Floor, No. 3 Building, Jinan Yaogu R&D Platform Area, No. 1 North Section of Gangxing No. 3 Road, Comprehensive Bonded Zone, Jinan High-tech Zone, Shandong Province Patentee after: Jinhe Tibetan Medicine (Shandong) Health Industry Co.,Ltd. Address before: First floor of Zhongliang Real Estate Group Center, No. 3 Longjing Second Road, Xin'an Street, Baoan District, Shenzhen City, Guangdong Province Patentee before: Shenzhen Shenxiang Society Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |